Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 3/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622341 | 0.82 | SMN1; SMN2 (0.59) | LMNASMN1; SMN2LIPEALDH1A1SCN9A | |
| SCHEMBL16726906 | 0.82 | L3MBTL1 (0.49) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL8686037 | 0.81 | L3MBTL1 (0.68) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL12929400 | 0.81 | SMN1; SMN2 (0.62) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL14769734 | 0.79 | L3MBTL1 (0.54) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL14769736 | 0.79 | L3MBTL1 (0.54) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL15979306 | 0.79 | L3MBTL1 (0.54) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL15449627 | 0.77 | L3MBTL1 (0.61) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL15382927 | 0.77 | MAPK1 (0.71) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 | |
| SCHEMBL14769737 | 0.76 | L3MBTL1 (0.51) | LMNASMN1; SMN2CYP2C9TSHRAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | LMNA 4191/4885SMN1; SMN2 2585/4885CYP2C9 670/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | LMNA 4191/4885SMN1; SMN2 2585/4885CYP2C9 670/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | LMNA 4540/4885SMN1; SMN2 4448/4885CYP2C9 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.